Cornerstone Capital’s Nephros NEPH Stock Holding History

Cornerstone Capital’s Portfolio NEPH Stock Details NEPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-128,700	Closed	-$459K	–	118
2026 Q2	$459K	Hold	128,700	–	–	0.04%	88
2026 Q1	$384K	Buy	+128,700	New	+$514K	0.04%	89

Other funds holding NEPH

Massachusetts Institute of Technology Cambridge, Massachusetts $695M AUM 43.77% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $763M AUM 59.25% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Meritage Group San Francisco, California $2.78B AUM 9.1% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Bard Associates Chicago, Illinois $431M AUM 30.93% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Mesirow Financial Investment Management Chicago, Illinois $6.47B AUM 15.41% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $106B AUM 21.33% 1-Year Est. Return

Cornerstone Capital's NEPH Position: Q3 2026 in Review

Cornerstone Capital sold out of Nephros (NEPH) in Q3 2026, closing a stake of 128,700 shares — an estimated $459K sold.

Cornerstone Capital first reported a position in NEPH in Q1 2026 and held it in 2 quarters. The position peaked at $459K in Q2 2026. 26 funds tracked by Wall St. Rank hold NEPH as of Q3 2026.

Cornerstone Capital reported no remaining Nephros position as of Q3 2026 after selling out during the quarter.
Cornerstone Capital sold 128,700 Nephros shares in Q3 2026, an estimated $459K.
Cornerstone Capital first reported a position in Nephros in Q1 2026 and held it in 2 quarters.
Cornerstone Capital's Nephros position peaked at $459K in Q2 2026.
26 funds tracked by Wall St. Rank held Nephros as of Q3 2026.

Based on Cornerstone Capital's 13F filing for Q3 2026, filed 10 Nov 2026.